Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13150847 | 0.84 | MAPT (0.53) | TDP1GAAKDM4EL3MBTL1MAPT | |
| SCHEMBL4174147 | 0.79 | TDP1 (0.39) | TDP1GAAPKMMAPTALDH1A1 | |
| SCHEMBL20049121 | 0.79 | NPC1 (0.40) | TDP1GAAKDM4EL3MBTL1MAPT | |
| SCHEMBL20049288 | 0.79 | ALDH1A1 (0.50) | TDP1GAAKDM4EL3MBTL1NPSR1 | |
| SCHEMBL4173884 | 0.79 | NR4A2 (0.39) | TDP1GAAPKMMAPTALDH1A1 | |
| SCHEMBL19535296 | 0.78 | TDP1 (0.58) | TDP1GAAKDM4EPKML3MBTL1 | |
| SCHEMBL29589829 | 0.78 | TDP1 (0.58) | TDP1GAAKDM4EPKML3MBTL1 | |
| SCHEMBL6305823 | 0.78 | GLP1R (0.58) | GLP1R | |
| SCHEMBL9901079 | 0.77 | GLP1R (0.36) | TDP1GLP1R | |
| SCHEMBL11327423 | 0.76 | MAPT (0.47) | TDP1GAAKDM4EL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| US-10889611-B2 | Sialyltransferase inhibitors and uses thereof | ACADEMIA SINICA (TW) | 2021-01-12 | — | — | US | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-6927214-B1 | Non-peptide GLP-1 agonists | NOVO NORDISK A/S (DK) | 2005-08-09 | — | — | US | disclosed |
| EP-1147094-A1 | NON-PEPTIDE GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042026-A1 | NON-PEPTIDE GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889611-B2 | Sialyltransferase inhibitors and uses thereof | ST6GAL1, NEU1, GALNT1 | TDP1 973/4885GAA 194/4885KDM4E 4044/4885 |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | TDP1 4116/4885GAA 1078/4885KDM4E 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.